Tiotropium plus Salmeterol; Fluticasone/Salmeterol
Проводит Boehringer Ingelheim
Страница компанииEffect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00530842/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 344 чел. во всех странах исследования.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 13 · невключение: 28
Критерии включения
- The patient has signed an Informed Consent Form in accordance with GCP and local legislative requirements prior to participation in the trial, i.e., prior to pre-trial washout of any restricted medications.
- The patient has a clinical diagnosis of chronic obstructive pulmonary disease (COPD).
- The patient has relatively stable, moderate to severe airway obstruction.
- The patient has a pre-bronchodilator forced expiratory volume in the first second (FEV1) less than or equal to 65% of predicted normal determined at Visit 1 using the following predicted equations (R94-1408):
- Males Forced expiratory volume in the first second (FEV1) predicted \[Litres (L)\] = 4.30 x Height \[metres\] minus 0.029 x Age \[years\] minus 2.49
- Females Forced expiratory volume in the first second (FEV1) predicted \[Litres (L)\] = 3.95 x Height \[metres\] minus 0.025 x Age \[years\] minus 2.60 and a Thoracic Gas Volume (Functional residual volume) ((TGV)(FRC)) bigger than 120% predicted normal at visit 1 (or historical data not older than 6 month)
- Males Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. \[Litres (L)\] = 2.34 x Height \[metres\] + 0.009 x Age \[years\] minus 1.09
- Females Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. \[Litres (L)\] = 2.24 x Height \[metres\] + 0.001 x Age \[years\] minus 1.00
- The patient is at least 40 years and less than or equal to 75 years old.
- The patient has a cigarette smoking history of at least 10 pack-years. A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for a year.
- The patient is able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
- The patient is able to inhale the trial medication from the HandiHaler device.
- The patient is able to inhale the trial medication from the Diskus/Accuhaler device.
Критерии невключения
- a significant disease other than chronic obstructive pulmonary disease (COPD). (review contraindications for exercise testing),
- a recent history of myocardial infarction within one year.
- a recent history of heart failure, pulmonary oedema, or patients with cardiac arrhythmia or any contraindication to exercise described in the CTProtocol within the last 3.
- daytime supplemental oxygen.
- a diagnosis of known active tuberculosis.
- a history of cancer within the last 5 years.
- a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
- thoracotomy with pulmonary resection.
- an upper respiratory tract infection or an exacerbation of chronic obstructive pulmonary disease (COPD)
- a known hypersensitivity to anticholinergic drug, ß-adrenergic or corticosteroids, lactose or any other component of the inhalation capsule delivery system.
- a known symptomatic prostatic hypertrophy or bladder neck obstruction.
- a known moderate or severe renal insufficiency.
- a known narrow-angle glaucoma.
- a known untreated hypokalemia.
- a known untreated thyrotoxicosis.
- a history of asthma, allergic rhinitis or atopy, or a total blood eosinophil count larger than 600/mm3.
- treatment with cromolyn sodium or nedocromil sodium
- treatment with antihistamines or antileukotrienes.
- treatment with tiotropium for 1 month before Visit 1.
- treatment with oral corticosteroid medication.
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
- a history of or active alcohol or drug abuse.
- an investigational drug within 1 month or 10 half lives
- a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea.
- participation in a rehabilitation program for chronic obstructive pulmonary disease (COPD).
- treatment with monoamine oxidase inhibitors inhibitors or tricyclic antidepressants.
- participation in another study.
- more than eight puffs of salbutamol/day during the run-in period
Источник: ClinicalTrials.gov, NCT00530842 · запись обновлена в реестре 24 декабря 2013.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 57
- Post-dose TGV(FRC) (After 8 Weeks) — 8 weeks
- Endurance Time (After 8 Weeks) — 8 weeks
Цель исследования
The primary objective of this study is to demonstrate that treatment with a free combination of tiotropium and salmeterol provides superior improvement in static lung volumes and exercise tolerance compared to a fixed combination of fluticasone and salmeterol in patients with COPD.
The secondary objective includes assessment of safety.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00530842 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.